Skip to main content
. Author manuscript; available in PMC: 2017 Sep 6.
Published in final edited form as: Leukemia. 2016 Dec 26;31(9):1872–1881. doi: 10.1038/leu.2016.382

Figure 4.

Figure 4

Effect of oral duvelisib therapy on expression of BCL2 family proteins in CLL lymphocytes after 28 days (C2D1; cycle 2 day 1) of oral duvelisib intake. (A–C) Reverse phase protein array (RPPA) analysis showing log2 difference in BCL2 family proteins expressions in CLL B cells isolated from patients before and after 28 days of duvelisib therapy (n=16). CLL cells were obtained pre and post duvelisib therapy and protein was extracted. Protein extracts were analyzed through reverse-phase protein array as described in the Methods section. Proteins that are not included were not available in the assay. Detailed information regarding median value and p values is provided in the Supplemental Table 4.